CASADEI GARDINI, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.962
AS - Asia 5.327
EU - Europa 4.759
SA - Sud America 835
Continente sconosciuto - Info sul continente non disponibili 325
AF - Africa 131
OC - Oceania 37
Totale 27.376
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.674
GB - Regno Unito 1.781
SG - Singapore 1.589
CN - Cina 1.026
IT - Italia 785
VN - Vietnam 687
HK - Hong Kong 648
BR - Brasile 641
BD - Bangladesh 443
SE - Svezia 438
FI - Finlandia 402
DE - Germania 386
FR - Francia 241
RU - Federazione Russa 207
TR - Turchia 186
ID - Indonesia 168
CA - Canada 161
IN - India 123
BG - Bulgaria 108
KR - Corea 84
IE - Irlanda 80
JP - Giappone 60
AR - Argentina 58
IQ - Iraq 48
NL - Olanda 47
MX - Messico 37
AE - Emirati Arabi Uniti 34
BE - Belgio 33
PK - Pakistan 33
UA - Ucraina 33
ZA - Sudafrica 33
AT - Austria 31
CH - Svizzera 26
CL - Cile 26
EC - Ecuador 26
TH - Thailandia 26
VE - Venezuela 25
PH - Filippine 23
SA - Arabia Saudita 23
CO - Colombia 22
JM - Giamaica 22
ES - Italia 21
EG - Egitto 20
RO - Romania 20
NZ - Nuova Zelanda 19
AU - Australia 17
PL - Polonia 17
MY - Malesia 16
MA - Marocco 15
PE - Perù 15
CR - Costa Rica 14
PT - Portogallo 14
JO - Giordania 13
CZ - Repubblica Ceca 12
KE - Kenya 12
LT - Lituania 12
PY - Paraguay 11
UZ - Uzbekistan 11
NP - Nepal 10
BZ - Belize 9
DZ - Algeria 9
NO - Norvegia 9
TN - Tunisia 9
DK - Danimarca 8
IL - Israele 8
IR - Iran 8
AZ - Azerbaigian 7
GT - Guatemala 7
SK - Slovacchia (Repubblica Slovacca) 7
TW - Taiwan 7
BO - Bolivia 6
DO - Repubblica Dominicana 6
OM - Oman 6
PS - Palestinian Territory 6
BY - Bielorussia 5
EE - Estonia 5
HN - Honduras 5
KZ - Kazakistan 5
SN - Senegal 5
SV - El Salvador 5
UY - Uruguay 5
BH - Bahrain 4
ET - Etiopia 4
GA - Gabon 4
HU - Ungheria 4
LU - Lussemburgo 4
NI - Nicaragua 4
RS - Serbia 4
TT - Trinidad e Tobago 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AL - Albania 3
CI - Costa d'Avorio 3
GR - Grecia 3
KG - Kirghizistan 3
KH - Cambogia 3
LK - Sri Lanka 3
MQ - Martinica 3
NG - Nigeria 3
PA - Panama 3
AO - Angola 2
Totale 27.004
Salva come PNG Salva come JPEG
Città #
Fairfield 2.212
Ashburn 1.740
Santa Clara 1.383
Southend 1.304
Singapore 1.071
Woodbridge 907
Seattle 887
Houston 792
Cambridge 732
Chandler 692
Wilmington 684
Hong Kong 632
San Jose 558
Council Bluffs 460
Helsinki 379
Dearborn 324
Nyköping 307
London 303
Ann Arbor 300
Beijing 205
New York 175
Ho Chi Minh City 164
San Diego 163
Los Angeles 160
Izmir 157
Dong Ket 155
Hanoi 149
Jakarta 147
The Dalles 142
Lauterbourg 110
Sofia 106
Phoenix 104
Princeton 103
Milan 98
Sunnyvale 94
Eugene 93
Chicago 92
Boardman 86
Hefei 80
Dublin 77
Shanghai 75
São Paulo 69
Modena 64
Buffalo 63
Dallas 55
Munich 55
Orem 53
Bremen 47
Tokyo 47
Seoul 46
Rome 37
Atlanta 36
Redondo Beach 36
Frankfurt am Main 31
Montreal 28
Redwood City 28
Toronto 28
Bupyeong-gu 27
Columbus 24
Da Nang 24
Mumbai 23
Brussels 22
Salt Lake City 22
Nuremberg 21
Bologna 20
Chennai 20
Naples 20
Norwalk 20
Springfield 20
Amsterdam 19
Auckland 19
Guangzhou 19
Rio de Janeiro 19
San Mateo 18
Baghdad 17
Haiphong 17
Johannesburg 17
Moscow 17
Paris 17
Zhengzhou 17
Belo Horizonte 16
Kunming 16
Quito 16
San Francisco 16
Turku 16
Brasília 15
Denver 15
Miano 15
Vienna 15
Charlotte 14
Falkenstein 14
Genoa 14
Jacksonville 14
Kingston 14
Santiago 14
Stockholm 14
Turin 14
Zurich 14
Portsmouth 13
Washington 13
Totale 19.876
Salva come PNG Salva come JPEG
Nome #
Chemotherapy and palliative care near end-of life: Examining the appropriateness at a cancer institute for colorectal cancer patients 626
Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: Indicators of suspected adverse reactions 510
Systematic versus on-demand early palliative care: results from a multicentre, randomised clinical trial 472
Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients 395
Metabolic disorders across hepatocellular carcinoma in Italy 387
Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis 368
Immunotherapy for colorectal cancer: where are we heading? 344
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals 337
In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3–mediated apoptosis 327
Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life 325
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol 325
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) 322
Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma 322
Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial 315
Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma 310
Alpha-fetoprotein surge following high-dose chemotherapy in germ cell tumours 309
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 307
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 302
Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows 298
Treatment of squamous cell carcinoma of the anal canal: A new strategies with anti-EGFR therapy and immunotherapy 298
Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals 296
1H-NMR based serum metabolomics highlights different specific biomarkers between early and advanced hepatocellular carcinoma stages 294
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 294
ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib 289
Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: Results from the ITACa randomized clinical trial 287
Prolonged pemetrexed infusion plus gemcitabine in refractory metastatic colorectal cancer: Preclinical rationale and phase II study results 286
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 285
Immunotherapeutic approaches for hepatocellular carcinoma 285
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 283
eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: Final results of the ePHAS study 280
Acute oxaliplatin-induced thrombotic thrombocytopenic purpura: A case report and results from a cytoflourimetric assay of platelet fibrinogen receptor 279
The Italian Rare Pancreatic Exocrine Cancer Initiative 275
Efficacy of sorafenib in BRAF-mutated nonsmall- cell lung cancer (NSCLC) and no response in synchronous BRAF wild typehepatocellular carcinoma: A case report 274
Comparing simultaneous integrated boost vs sequential boost in anal cancer patients: results of a retrospective observational study 274
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation 271
KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC) 264
Aberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities 264
Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials 263
Right- vs. left-sided metastatic colorectal cancer: Differences in tumor biology and bevacizumab efficacy 263
Complete Response in Patient with Metastatic Breast Cancer Treated with Metronomic Chemotherapy 263
Cytoreduction plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis in colorectal cancer patients: a single-center cohort study 262
Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study 262
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib 262
No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC) 261
Prognostic role of aspartate aminotransferase-lymphocyte ratio index in patients with metastatic colorectal cancer: results from the randomized ITACa trial 260
Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of bevacizumab efficacy in patients with metastatic colorectal cancer 258
Multimodal treatment of resectable pancreatic ductal adenocarcinoma 257
The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer 254
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 253
Increase of reports of suspected adverse drug reactions in oncology 253
Multicentric prospective study of validation of angiogenesis polymorphisms in HCC patients treated with sorafenib. INNOVATE study 252
Chemoradiotherapy (Gemox plus helical tomotherapy) for unresectable locally advanced pancreatic cancer: A phase II study 251
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 251
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma 250
BRAF-mutated colorectal cancer: Clinical and molecular insights 250
EGFR, HER-2 and KRAS in canine gastric epithelial tumors: A potential human model? 249
Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: Colon Inflammatory Index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal Cancer (ITACa) study 246
Improved stool DNA integrity method for early colorectal cancer diagnosis 244
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 243
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 242
Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients 239
Sarcopenia in gastric cancer: when the loss costs too much 239
Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study 237
Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials 237
Radiofrequency Ablation of hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-free survival 236
Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease 236
Shifts of Faecal Microbiota during Sporadic Colorectal Carcinogenesis 236
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 235
Fecal DNA for noninvasive diagnosis of colorectal cancer in immunochemical fecal occult blood test-positive individuals 235
Atypical presentations of thrombotic thrombocytopenic purpura in middle-aged women with recurrent cerebral macrovascular thrombosis: a case report 232
Paraneoplastic lipase and amylase production in a patient with small-cell lung cancer: Case report 230
Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin 225
Clustered protocadherins methylation alterations in cancer 222
Sorafenib and Regorafenib in HBV- or HCV-positive hepatocellular carcinoma patients: Analysis of RESORCE and SHARP trials 222
Hemangioblastoma of the gastrointestinal tract: A first case 220
Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab 219
Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced hcc patients treated with sorafenib: Results from a retrospective analysis of the HCC-AVR group 218
Systematic vs. on-demand early palliative care in gastric cancer patients: a randomized clinical trial assessing patient and healthcare service outcomes 215
Erratum to “Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life” [Eur J Cancer (2016) 69 (110–118)] (S095980491632487X)(10.1016/j.ejca.2016.10.004) 215
NMR-Based Metabolomic Approach Tracks Potential Serum Biomarkers of Disease Progression in Patients with Type 2 Diabetes Mellitus 205
Treatment of squamous cell carcinoma of the anal canal (SCCA): A new era? 204
Impact of physician experience and multidisciplinary team on clinical outcome in patients receiving sorafenib 203
Promoter methylation of tumor suppressor genes in pre-neoplastic lesions; Potential marker of disease recurrence 200
Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colorectal cancer: Results from the ITACa trial 198
NEMESI: A retrospective observational longitudinal study to investigate italian early breast cancer (EBC) patient characteristics and treatment 195
Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? 192
Immunotherapy for hepatocellular carcinoma: A review of potential new drugs based on ongoing clinical studies as of 2019 189
Platelets and Hepatocellular Cancer: Bridging the Bench to the Clinics 189
Prevalence of and risk factors for fatty liver in the general population of Northern Italy: The Bagnacavallo Study 187
Retrospective Analysis on the Management of Metastatic Gastric Cancer Patients. A Mono-institutional Experience. What happens in Clinical Practice? 186
IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab 185
Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience 175
Long-term complete response in a patient with liver metastases from breast cancer treated with metronomic chemotherapy 174
Overview of prognostic systems for hepatocellular carcinoma and ITA.LI.CA external validation of MESH and CNLC classifications 171
Incorporating alpha-fetoprotein within dimensional criteria for hepatocellular carcinoma transplantation 169
Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort 168
Oxidative Molecular Mechanisms Underlying Liver Diseases: From Systems Biology to the Personalized Medicine 167
mTOR Pathway Expression as Potential Predictive Biomarker in Patients with Advanced Neuroendocrine Tumors Treated with Everolimus 164
BRCA in Gastrointestinal Cancers: Current Treatments and Future Perspectives 163
Critical systematic review on hepatic resection and transarterial chemoembolization for hepatocellular carcinoma 163
Totale 26.023
Salva come PNG Salva come JPEG
Categoria #
all - tutte 111.167
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 111.167
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.638 0 0 0 113 68 185 81 122 224 259 376 210
2022/20232.022 227 196 130 174 279 237 65 215 288 21 94 96
2023/2024900 41 77 50 120 141 32 68 126 22 25 29 169
2024/20254.052 133 39 33 256 957 686 433 227 449 167 212 460
2025/20267.151 383 232 384 533 913 393 913 412 740 801 810 637
2026/20271.665 303 616 446 300 0 0 0 0 0 0 0 0
Totale 27.376